Literature DB >> 22812582

Glucocerebrosidase mutations in a Serbian Parkinson's disease population.

K R Kumar1, A Ramirez, A Göbel, N Kresojević, M Svetel, K Lohmann, C M Sue, A Rolfs, J R Mazzulli, R N Alcalay, D Krainc, C Klein, V Kostic, A Grünewald.   

Abstract

BACKGROUND AND
PURPOSE: To screen for glucocerebrosidase (GBA) mutations in a Serbian Parkinson's disease (PD) population.
METHODS: Glucocerebrosidase exons 8-11 harbouring the most common mutations were sequenced in 360 patients with PD and 348 controls from Serbia. Haplotype analysis was performed for the N370S mutation and compared with German and Ashkenazi Jewish carriers.
RESULTS: Glucocerebrosidase mutations were significantly more frequent in patients with PD (21/360; 5.8%) vs. controls (5/348; 1.4%; OR = 4.25; CI, 1.58-11.40; P = 0.0041). Two patients with PD carried homozygous or compound heterozygous mutations in GBA. The N370S mutation accounted for about half of the mutated alleles in patients (10/23) but was absent amongst controls. Three novel variants were detected including two non-synonymous variants (D380V, N392S) in the patient group and one synonymous change (V459V) in a control. Carriers of the D409H mutation were also sequenced for H255Q, and all were found to carry the [D409H; H255Q] double-mutant allele. Genotyping suggested a common haplotype for all N370S carriers.
CONCLUSION: Glucocerebrosidase mutations represent a PD risk factor in the Serbian population.
© 2012 The Author(s) European Journal of Neurology © 2012 EFNS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22812582     DOI: 10.1111/j.1468-1331.2012.03817.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  16 in total

Review 1.  GBA-Associated Parkinson's Disease and Other Synucleinopathies.

Authors:  Ziv Gan-Or; Christopher Liong; Roy N Alcalay
Journal:  Curr Neurol Neurosci Rep       Date:  2018-06-08       Impact factor: 5.081

Review 2.  Association of gender and age at onset with glucocerebrosidase associated Parkinson's disease: a systematic review and meta-analysis.

Authors:  Qinghua Li; Yajun Jing; Peng Lun; Xia Liu; Peng Sun
Journal:  Neurol Sci       Date:  2021-04-10       Impact factor: 3.307

3.  Differential effects of severe vs mild GBA mutations on Parkinson disease.

Authors:  Ziv Gan-Or; Idan Amshalom; Laura L Kilarski; Anat Bar-Shira; Mali Gana-Weisz; Anat Mirelman; Karen Marder; Susan Bressman; Nir Giladi; Avi Orr-Urtreger
Journal:  Neurology       Date:  2015-02-04       Impact factor: 9.910

Review 4.  Genetic convergence of Parkinson's disease and lysosomal storage disorders.

Authors:  Hao Deng; Xiaofei Xiu; Joseph Jankovic
Journal:  Mol Neurobiol       Date:  2014-08-07       Impact factor: 5.590

5.  Glucocerebrosidase and parkinsonism: lessons to learn.

Authors:  Ivanka Marković; Nikola Kresojević; Vladimir S Kostić
Journal:  J Neurol       Date:  2016-03-19       Impact factor: 4.849

Review 6.  Glucocerebrosidase is shaking up the synucleinopathies.

Authors:  Marina Siebert; Ellen Sidransky; Wendy Westbroek
Journal:  Brain       Date:  2014-02-14       Impact factor: 13.501

Review 7.  Glucocerebrosidase and Parkinson disease: Recent advances.

Authors:  Anthony H V Schapira
Journal:  Mol Cell Neurosci       Date:  2015-03-20       Impact factor: 4.314

8.  Effect of GBA Mutations on Phenotype of Parkinson's Disease: A Study on Chinese Population and a Meta-Analysis.

Authors:  Yuan Zhang; Qi-Ying Sun; Yu-Wen Zhao; Li Shu; Ji-Feng Guo; Qian Xu; Xin-Xiang Yan; Bei-Sha Tang
Journal:  Parkinsons Dis       Date:  2015-09-02

Review 9.  The relationship between glucocerebrosidase mutations and Parkinson disease.

Authors:  Anna Migdalska-Richards; Anthony H V Schapira
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

Review 10.  The Neuropsychiatric and Motor Profile of GBA-Associated Parkinson's Disease: A Review.

Authors:  Gian Pal; Erin Robertson; Joan O'Keefe; Deborah Hall
Journal:  Mov Disord Clin Pract       Date:  2015-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.